Inflammatory and toxic myopathy

Seminars in Neurology

Volumn 32, Issue 5, 2012, Pages 491-499

  Teener, James W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

cholesterol lowering agent myopathy; dermatomyositis; inclusion body myositis; myositis; necrotizing myopathy; polymyositis; toxic myopathy

Indexed keywords

AMIODARONE; ANTILIPEMIC AGENT; AZATHIOPRINE; CERIVASTATIN; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIDANOSINE; EMETINE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISONE; RITUXIMAB; SIMVASTATIN; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ALOPECIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTRODIAGNOSIS; ELECTROLYTE DISTURBANCE; FEVER; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GOUT; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERTRICHOSIS; IMMUNE NECROTIZING MYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATORY DISEASE; INFLAMMATORY NECROTIZING MYOPATHY; LEUKOPENIA; LIVER TOXICITY; LUNG FIBROSIS; MUSCLE BIOPSY; MUSCLE FUNCTION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NONHUMAN; PANCREATITIS; PERIPHERAL EDEMA; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; RHABDOMYOLYSIS; STOMATITIS; TERATOGENICITY; TREMOR; VOMITING;

ANIMALS; ANTINEMATODAL AGENTS; ANTIRHEUMATIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MUSCLE, SKELETAL; MUSCULAR DISEASES; TREATMENT OUTCOME;

EID: 84878046221     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0033-1334467     Document Type: Article

References (41)

1. Amato A. A., Barohn R. J. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry: 2009; 80 10 1060 1068
2. Hochberg M. C., Feldman D., Stevens M. B. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum: 1986; 15 3 168 178
3. Bohan A., Peter J. B., Bowman R. L., Pearson C. M. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore): 1977; 56 4 255 286
4. Nozaki K., Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry: 2009; 80 8 904 908
5. Hengstman G. J., van Engelen B. G., van Venrooij W. J. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol: 2004; 16 6 692 699
6. Hengstman G. J., ter Laak H. J., Vree Egberts W. T., et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis: 2006; 65 12 1635 1638
7. Rutkove S. B., De Girolami U., Preston D. C., et al. Myotonia in colchicine myoneuropathy. Muscle Nerve: 1996; 19 7 870 875
8. Rich M. M., Teener J. W., Raps E. C., Schotland D. L., Bird S. J. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology: 1996; 46 3 731 736
9. Rich M. M., Pinter M. J., Kraner S. D., Barchi R. L. Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol: 1998; 43 2 171 179
10. Arahata K., Engel A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol: 1984; 16 2 193 208
11. Engel A. G., Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol: 1984; 16 2 209 215
12. Amato A. A., Barohn R. J. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry: 2009; 80 11 1186 1193
13. Bronner I. M., Hoogendijk J. E., Wintzen A. R., et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol: 2003; 250 4 480 485
14. Emslie-Smith A. M., Engel A. G. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology: 1991; 41 6 936 939
15. Callen J. P. Relationship of cancer to inflammatory muscle diseases. Dermatomyositis, polymyositis, and inclusion body myositis. Rheum Dis Clin North Am: 1994; 20 4 943 953
16. Joffe M. M., Love L. A., Leff R. L., et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med: 1993; 94 4 379 387
17. Kissel J. T., Levy R. J., Mendell J. R., Griggs R. C. Azathioprine toxicity in neuromuscular disease. Neurology: 1986; 36 1 35 39
18. Majithia V., Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford): 2005; 44 3 386 389
19. Goei The H. S., Jacobs P., Houben H. Cyclosporine in the treatment of intractable polymyositis. Arthritis Rheum: 1985; 28 12 1436 1437
20. Oddis C. V., Sciurba F. C., Elmagd K. A., Starzl T. E. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet: 1999; 353 9166 1762 1763
21. Cronin M. E., Miller F. W., Hicks J. E., Dalakas M., Plotz P. H. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol: 1989; 16 9 1225 1228
22. Fries J. F., Sharp G. C., McDevitt H. O., Holman H. R. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. Arthritis Rheum: 1973; 16 2 154 162
23. Sinoway P. A., Callen J. P. Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum: 1993; 36 3 319 324
24. Dalakas M. C., Illa I., Dambrosia J. M., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med: 1993; 329 27 1993 2000
25. Hennekens C. H. Statin-induced myopathy: hypothesis about randomized evidence and clinical impressions. Am J Med: 2009; 122 1 4 5
26. McAdams M., Staffa J., Dal Pan G. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf: 2008; 17 3 229 239
27. Vladutiu G. D. Genetic predisposition to statin myopathy. Curr Opin Rheumatol: 2008; 20 6 648 655
28. Grable-Esposito P., Katzberg H. D., Greenberg S. A., Srinivasan J., Katz J., Amato A. A. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve: 2010; 41 2 185 190
29. Walsh R. J., Amato A. A. Toxic myopathies. Neurol Clin: 2005; 23 2 397 428
30. Kuncl R. W., Duncan G., Watson D., Alderson K., Rogawski M. A., Peper M. Colchicine myopathy and neuropathy. N Engl J Med: 1987; 316 25 1562 1568
31. Kuncl R. W., Cornblath D. R., Avila O., Duncan G. Electrodiagnosis of human colchicine myoneuropathy. Muscle Nerve: 1989; 12 5 360 364
32. Kiyomoto B. H., Tengan C. H., Godinho R. O. Effects of short-term zidovudine exposure on mitochondrial DNA content and succinate dehydrogenase activity of rat skeletal muscle cells. J Neurol Sci: 2008; 268 1-2 33 39
33. Mhiri C., Baudrimont M., Bonne G., et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol: 1991; 29 6 606 614
34. Pascuzzi R. M. Drugs and toxins associated with myopathies. Curr Opin Rheumatol: 1998; 10 6 511 520
35. Kissel J. T., Mendell J. R. The endocrine myopathies. In: Rowland L. P., DiMauro S., eds. Handbook of Clinical Neurology. Amsterdam Elsevier: 1992; 527 551
36. Faludi G., Gotlieb J., Meyers J. Factors influencing the development of steroid-induced myopathies. Ann N Y Acad Sci: 1966; 138 1 62 72
37. Hirano M., Ott B. R., Raps E. C., et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology: 1992; 42 11 2082 2087
38. MacFarlane I. A., Rosenthal F. D. Severe myopathy after status asthmaticus. Lancet: 1977; 2 8038 615
39. Lacomis D., Petrella J. T., Giuliani M. J. Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve: 1998; 21 5 610 617
40. Palmer E. P., Guay A. T. Reversible myopathy secondary to abuse of ipecac in patients with major eating disorders. N Engl J Med: 1985; 313 23 1457 1459
41. Amato A. A., Kagan-Hallet K., Jackson C. E., et al. The wide spectrum of myofibrillar myopathy suggests a multifactorial etiology and pathogenesis. Neurology: 1998; 51 6 1646 1655